Irbesartan:回顾它的使用在高血压和糖尿病肾病的管理。

文章的细节

引用

复制到剪贴板

Croom KF,柯伦MP,果阿KL,佩里厘米

Irbesartan:回顾它的使用在高血压和糖尿病肾病的管理。

药。2004;64 (9):999 - 1028。

PubMed ID

15101793 (在PubMed

]

文摘

Irbesartan (Avapro Aprovel)是一种有效和选择性血管紧张素ⅱ1亚型受体拮抗剂表示用于高血压患者,其中包括2型糖尿病和肾病。每天换一次irbesartan管理局提供24小时血压(BP)的控制。轻度到中度高血压患者irbesartan卡托普利一样有效,阿替洛尔和氨氯地平,比缬沙坦的绝对更有效降低BP和响应率。Irbesartan产生更大的降低舒张压在槽比每日一次洛沙坦,但比olmesartan影响较小;达到降低收缩压与irbesartan相似或高于与洛沙坦与olmesartan很相似。irbesartan的组合与氢氯噻嗪生产添加剂对英国石油公司减少的影响。Irbesartan也诱导高血压患者左心室质量的回归和左心室肥大。在两个大的研究(IRbesartan微蛋白尿2型糖尿病高血压患者[厄玛2]和IRbesartan糖尿病肾病试验[IDNT]) IRbesartan施加renoprotective效应与2型糖尿病的高血压患者在糖尿病肾病的早期和后期。renoprotective效应至少在一定程度上独立于BP-lowering效果。在厄玛2试验,发展到公开的肾病患者的比例显著降低的接受者比安慰剂irbesartan 300毫克每日一次。 In patients with overt nephropathy in the IDNT, irbesartan 300mg once daily provided significantly greater renoprotection than amlodipine 10mg once daily or placebo. The relative risk of doubling of serum creatinine was significantly lower with irbesartan than amlodipine or placebo. Irbesartan is well tolerated in hypertensive patients, including those with type 2 diabetes and incipient or overt nephropathy. The overall incidence of adverse events with irbesartan was similar to that with placebo. Irbesartan was associated with a lower incidence of cough than enalapril and was not associated with ankle oedema or with any clinically significant drug interactions. In conclusion, irbesartan is a well tolerated and effective antihypertensive agent. It also slows the progression of renal disease in hypertensive patients with type 2 diabetes at both the early and later stages of diabetic nephropathy. Thus, irbesartan is a valuable agent in the management of patients with these indications.

DrugBank数据引用了这篇文章

药物

Irbesartan

药物靶点

药物	目标	类	生物	药理作用	行动
Irbesartan	1型血管紧张素ⅱ受体	蛋白质	人类	是的	拮抗剂	细节